Author/Authors :
Nourinia, Ramin Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ahmadieh, Hamid Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Rezaei-Kanavi, Mozhgan Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Kamrava, Kiana Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Karimi, Saeed Ophthalmic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Shoeibi, Nasser Retina Research Center - Khatam-Al-Anbia Eye Hospital - Mashhad University of Medical Sciences, Mashhad, Iran
Abstract :
Purpose: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye.
Methods: Twenty eyes of 20 pigmented rats were randomized into five groups to
receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced
salt solution (BSS). One week and one month after the injections, all eyes were evaluated for intraocular inflammation. Electroretinography (ERG) was performed before, and one week and one month after the injections. All eyes were enucleated one month after the injection for histologic examination.
Results: No significant inflammatory response was observed in any eye. No significant
decrease in ERG amplitude (a & b waves) was observed one week and one month after intravitreal ZA injection, as compared to baseline, BSS-treated eyes or non-injected fellow eyes. Histologic examination of the retinal pigment epithelium and neurosensory retina were unremarkable in all groups. Additionally, no significant increase in immune reactivity for glial fibrillary acidic protein was noted in any eye.
Conclusion: Based on clinical, histopathologic and ERG findings in this experimental
study, up to 8 mcg of intravitreal zoledronic acid seems to be safe in the rat eye.
